DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



RATe Control in Atrial Fibrillation

Information source: Asker & Baerum Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Atrial Fibrillation

Intervention: Metoprolol (Drug); Diltiazem (Drug); Verapamil (Drug); Carvedilol (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Asker & Baerum Hospital

Official(s) and/or principal investigator(s):
Sara Reinvik Fagertun, MD, Principal Investigator, Affiliation: Asker and Baerum Hospital

Summary

The purpose of this study is to compare the effect of metoprolol, verapamil, diltiazem and carvedilol on ventricular rate, working capacity and quality of life in patients with chronic atrial fibrillation.

Clinical Details

Official title: Rate Control in Atrial Fibrillation

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment

Primary outcome: Ventricular rate

Detailed description: This is a randomised, single blinded, cross-over study comparing the efficacy of metoprolol 100 mg o. d., verapamil 240 mg o. d., diltiazem 360 mg o. d. and carvedilol 25 mg o. d. in reducing ventricular rate in atrial fibrillation. A total of 60 patients will be included, with a minimum of 20 women. Patients will receive each of the drug regimens in a random sequence. Each regimen will be administered for 3 weeks, ensuring that steady-state drug concentration will be attained and to provide an adequate washout of the previous treatment. Following each regimen, exercise ECG and Holter registration will be performed and patients will undergo laboratory evaluation and complete QoL-forms. They will then be started on the next randomly assigned treatment regimen, until the entire sequence of treatment schedules is completed.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Persistent or permanent atrial fibrillation with ventricular rate > 80/min at rest

and/or > 100/min average at daytime.

- Male or female, age > 18.

Exclusion Criteria:

- Hypersensitivity or contraindication to metoprolol, verapamil, diltiazem or

carvedilol.

- Coronary heart disease or heart failure

- Systolic blood pressure < 100 mmHg

- AV-conduction disturbance

- Severe hepatic or renal dysfunction

- Thyrotoxicosis

- Ongoing treatment with Digitalis

- Pregnancy or lactation

Locations and Contacts

Vestre Viken Hospital Trust, Baerum Hospital, Rud, Akershus 1309, Norway
Additional Information

Starting date: April 2006
Last updated: May 11, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017